NO973529D0 - Anvendelse av 5'-substituerte nukleosider for å hemme resistensdannelse ved cytostatisk behandling og legemidler inneholdende slike nukleosider - Google Patents
Anvendelse av 5'-substituerte nukleosider for å hemme resistensdannelse ved cytostatisk behandling og legemidler inneholdende slike nukleosiderInfo
- Publication number
- NO973529D0 NO973529D0 NO973529A NO973529A NO973529D0 NO 973529 D0 NO973529 D0 NO 973529D0 NO 973529 A NO973529 A NO 973529A NO 973529 A NO973529 A NO 973529A NO 973529 D0 NO973529 D0 NO 973529D0
- Authority
- NO
- Norway
- Prior art keywords
- nucleosides
- cytostatic
- bvdu
- cytostatic treatment
- resistance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19503152 | 1995-02-01 | ||
DE19545892A DE19545892A1 (de) | 1995-12-08 | 1995-12-08 | Verwendung von (E)-5-(2-Bromovinyl-)-2'-deoxyuridine (BVDU) zur Resistenzbildung bei der Zytostatikabehandlung und Arzneimittel, enthaltend BVDU |
PCT/DE1996/000169 WO1996023506A1 (de) | 1995-02-01 | 1996-01-31 | Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside |
Publications (3)
Publication Number | Publication Date |
---|---|
NO973529D0 true NO973529D0 (no) | 1997-07-31 |
NO973529L NO973529L (no) | 1997-10-01 |
NO315258B1 NO315258B1 (no) | 2003-08-11 |
Family
ID=26012025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19973529A NO315258B1 (no) | 1995-02-01 | 1997-07-31 | Anvendelse av 5'-substituerte nukleosider |
Country Status (12)
Country | Link |
---|---|
US (1) | US6589941B1 (no) |
EP (1) | EP0806956B1 (no) |
JP (1) | JPH11502515A (no) |
KR (1) | KR100330602B1 (no) |
AT (1) | ATE222765T1 (no) |
BR (1) | BR9607109A (no) |
DE (1) | DE59609590D1 (no) |
DK (1) | DK0806956T3 (no) |
ES (1) | ES2180730T3 (no) |
NO (1) | NO315258B1 (no) |
PT (1) | PT806956E (no) |
WO (1) | WO1996023506A1 (no) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE413881T1 (de) * | 1997-08-08 | 2008-11-15 | Celmed Oncology Usa Inc | Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden |
ATE212661T1 (de) | 1998-01-23 | 2002-02-15 | Newbiotics Inc | Durch enzymkatalyse erhaltene therapeutische substanzen. |
US7462605B2 (en) * | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
DE19842578A1 (de) * | 1998-09-17 | 2000-03-23 | Max Delbrueck Centrum | Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zum Herabsetzen thrombocytopenischer Nebenwirkungen von Cytostatika |
CA2378187C (en) | 1999-07-22 | 2011-09-13 | Newbiotics, Inc. | Methods for treating therapy-resistant tumors |
US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
US20030212037A1 (en) * | 2000-12-21 | 2003-11-13 | Christopher Boyer | Use of bvdu for inhibiting the growth of hyperproliferative cells |
EP1251836A2 (en) * | 1999-12-23 | 2002-10-30 | NewBiotics, Inc. | Use of bvdu for inhibiting the growth of hyperproliferative cells |
EP1359921A4 (en) | 2001-01-19 | 2006-09-06 | Newbiotics Inc | METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES |
DE10108851A1 (de) * | 2001-02-23 | 2002-09-12 | Resprotect Gmbh | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
DE10313035A1 (de) * | 2003-03-24 | 2004-10-07 | Resprotect Gmbh | Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen |
US20060269596A1 (en) * | 2005-01-12 | 2006-11-30 | Gary Liversidge | Controlled release compositions comprising an acylanilide |
HUP0600042A3 (en) * | 2006-01-19 | 2012-12-28 | Debreceni Egyetem | New medical use of thiolated pyrimidine-mononucleotides and -nucleosides |
DE102006037786A1 (de) | 2006-08-11 | 2008-03-20 | Resprotect Gmbh | Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US20090068286A1 (en) * | 2007-09-11 | 2009-03-12 | Resprotect, Gmbh | Method of treating cancer by administration of 5-substituted nucleosides |
EP2135601A1 (en) * | 2008-06-20 | 2009-12-23 | Capsulution Nanoscience AG | Stabilization of amorphous drugs using sponge-like carrier matrices |
DE102008030091B4 (de) | 2008-06-25 | 2011-03-03 | Resprotect Gmbh | Uracilderivate und deren Verwendung |
WO2012040127A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1069096A (en) * | 1962-11-23 | 1967-05-17 | Ile De Rech S Scient Et Ind So | New organic derivatives of nucleotides and method for their manufacture |
GB1473148A (no) * | 1974-09-16 | 1977-05-11 | ||
US4902678A (en) * | 1982-02-12 | 1990-02-20 | Syntex (U.S.A.) Inc. | Anti-viral compositions |
NL8700366A (nl) * | 1987-02-13 | 1988-09-01 | Stichting Rega V Z W | Combinatie van fu met bvdu als middel tegen adenocarcinoom. |
US5250296A (en) * | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
US6011000A (en) * | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
US5831064A (en) | 1996-07-25 | 1998-11-03 | The Trustees Of Columbia University In The City Of New York | Kaposi's sarcoma-associated herpes virus (KSHV) interferon consensus sequence binding protein (ICSBP) and uses thereof |
ATE212661T1 (de) | 1998-01-23 | 2002-02-15 | Newbiotics Inc | Durch enzymkatalyse erhaltene therapeutische substanzen. |
-
1996
- 1996-01-31 KR KR1019970705259A patent/KR100330602B1/ko active IP Right Grant
- 1996-01-31 EP EP96901696A patent/EP0806956B1/de not_active Expired - Lifetime
- 1996-01-31 WO PCT/DE1996/000169 patent/WO1996023506A1/de active IP Right Grant
- 1996-01-31 PT PT96901696T patent/PT806956E/pt unknown
- 1996-01-31 AT AT96901696T patent/ATE222765T1/de active
- 1996-01-31 DE DE59609590T patent/DE59609590D1/de not_active Expired - Lifetime
- 1996-01-31 JP JP8523173A patent/JPH11502515A/ja active Pending
- 1996-01-31 DK DK96901696T patent/DK0806956T3/da active
- 1996-01-31 BR BR9607109A patent/BR9607109A/pt not_active Application Discontinuation
- 1996-01-31 ES ES96901696T patent/ES2180730T3/es not_active Expired - Lifetime
-
1997
- 1997-07-31 NO NO19973529A patent/NO315258B1/no not_active IP Right Cessation
-
2000
- 2000-03-07 US US09/520,901 patent/US6589941B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0806956A1 (de) | 1997-11-19 |
BR9607109A (pt) | 1997-11-04 |
NO315258B1 (no) | 2003-08-11 |
DE59609590D1 (de) | 2002-10-02 |
ES2180730T3 (es) | 2003-02-16 |
DK0806956T3 (da) | 2003-01-06 |
US6589941B1 (en) | 2003-07-08 |
PT806956E (pt) | 2003-01-31 |
MX9705758A (es) | 1997-10-31 |
WO1996023506A1 (de) | 1996-08-08 |
ATE222765T1 (de) | 2002-09-15 |
EP0806956B1 (de) | 2002-08-28 |
KR19980701862A (ko) | 1998-06-25 |
JPH11502515A (ja) | 1999-03-02 |
KR100330602B1 (ko) | 2002-08-22 |
NO973529L (no) | 1997-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO973529D0 (no) | Anvendelse av 5'-substituerte nukleosider for å hemme resistensdannelse ved cytostatisk behandling og legemidler inneholdende slike nukleosider | |
CA2103458A1 (en) | Method and composition to reduce myocardial reperfusion injury | |
CA2225808A1 (en) | Silver-based pharmaceutical compositions | |
DE69226624D1 (de) | Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung | |
PL316080A1 (en) | Pharmaceutic composition for sublingual or intrabuccal administration | |
DE3587434D1 (de) | Antivirale pharmazeutische zusammensetzungen und ihrer verwendung. | |
CA2158475A1 (en) | Composition and method for reducing toxicity of biologically-active factors | |
WO2000002549A8 (en) | Composition for and method of treating neurological disorders | |
GR3022862T3 (en) | Pharmaceutical composition for treating nicotine dependence. | |
CA2283399A1 (en) | Pyridazinones as inhibitors of cyclooxygenase-2 | |
EP0654038A4 (en) | PHARMACEUTICAL FORMULATIONS WITH REGULATED RELEASE OF 3'-AZIDO-3'-DESOXYTHYMIDINE. | |
IL122960A0 (en) | Pharmaceutical compositions for use in the treatment of colonic adenomas | |
CA2275167A1 (en) | The topical use of kappa opioid agonists to treat ocular pain | |
ES2180564T3 (es) | 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina. | |
WO1999061010A3 (en) | Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound | |
CA2132544A1 (en) | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy | |
MX9504023A (es) | Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion. | |
BE901301A (fr) | 5-pyrimidine-carboxamides et thiocarboamides, ainsi que le traitement de la leucemie et des tumeurs avec ces substances. | |
CA2282279A1 (en) | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions | |
CA2198580A1 (en) | Combination therapy to treat osteoporosis | |
WO1999045909A3 (en) | Use of nitrone compounds for the inhibition of angiogenesis | |
EP0733640A4 (en) | TWO-YEAR OLIGONUCLEOTIDE AND CARCINOSTATIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | |
HK1015692A1 (en) | Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections | |
CA2330424A1 (en) | Improved method for eradication of helicobacter pylori | |
GR3034142T3 (en) | Composition for the treatment or prevention of herpes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |